WNT10A Plays an Oncogenic Role in Renal Cell Carcinoma by Activating WNT/β-catenin Pathway

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Hsu, Ren Jun ^a   Ho, Jar Yi ^a,b   Cha, Tai Lung ^a,b   Yu, Dah Shyong ^a,b   Wu, Chieh Lin ^a   Huang, Wei Ping ^a   Chu, Pauling ^a   Chen, Ying Hsin ^a   Chen, Jiann Torng ^a   Yu, Cheng Ping ^a,b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CISPLATIN; EPIRUBICIN; WNT10A PROTEIN;

ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CANCER TISSUE; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFORMATION; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; GAIN OF FUNCTION MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY CELL; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; ONCOGENE; PROTEIN EXPRESSION; RISK FACTOR; SIGNAL TRANSDUCTION; UPREGULATION; WNT SIGNALING PATHWAY;

ADULT; BETA CATENIN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; RISK FACTORS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 84867673480     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047649     Document Type: Article

References (91)

1. Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, et al. (2011) The epidemiology of renal cell carcinoma. Eur Urol 60: 615-621.
2. Bureau of Health Promotion, Department of Health, ROC (Taiwan) website. Available: http://www.bhp.doh.gov.tw/BHPnet/English/Class.aspx?Sub=statistics&No=200705180025. Accessed 2012 Sep 25.
3. Schedl A, (2007) Renal abnormalities and their developmental origin. Nat Rev Genet 8: 791-802.
4. Banumathy G, Cairns P, (2010) Signaling pathways in renal cell carcinoma. Cancer Biol Ther 10: 658-664.
5. McCoy KE, Zhou X, Vize PD, (2011) Non-canonical wnt signals antagonize and canonical wnt signals promote cell proliferation in early kidney development. Dev Dyn 240: 1558-1566.
6. Olson DJ, Gibo DM, (1998) Antisense wnt-5a mimics wnt-1-mediated C57MG mammary epithelial cell transformation. Exp Cell Res 241: 134-141.
7. Kühl M, Sheldahl LC, Park M, Miller JR, Moon RT, (2000) The Wnt/Ca2+ pathway: a new vertebrate wnt signaling pathway takes shape. Trends Genet 16: 279-283.
8. Klaus A, Birchmeier W, (2008) Wnt signalling and its impact on development and cancer. Nat Rev Cancer 8: 387-398.
9. Polakis P, (2007) The many ways of Wnt in cancer. Curr Opin Genet Dev 17: 45-51.
10. Roberts DM, Slep KC, Peifer M, (2007) It takes more than two to tango: Dishevelled polymerization and Wnt signaling. Nat Struct Mol Biol 14: 463-465.
11. Schmidt-Ott KM, Barasch J, (2008) WNT/beta-catenin signaling in nephron progenitors and their epithelial progeny. Kidney Int 74: 1004-1008.
12. Kikuchi A, Yamamoto H, (2008) Tumor formation due to abnormalities in the beta-catenin-independent pathway of Wnt signaling. Cancer Sci 99: 202-208.
13. Sugimura R, Li L, (2010) Noncanonical Wnt signaling in vertebrate development, stem cells, and diseases. Birth Defects Res C Embryo Today 90: 243-256.
14. Li Y, Welm B, Podsypanina K, Huang S, Chamorro M, et al. (2003) Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci USA 100: 15853-15858.
15. Gelebart P, Anand M, Armanious H, Peters AC, Dien Bard J, et al. (2008) Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. Blood 112: 5171-5179.
16. Kwan H, Pecenka V, Tsukamoto A, Parslow TG, Guzman R, et al. (1992) Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice. Mol Cell Biol 12: 147-154.
17. Lane TF, Leder P, (1997) Wnt-10b directs hypermorphic development and transformation in mammary glands of male and female mice. Oncogene 15: 2133-2144.
18. Baldewijns MM, van Vlodrop IJ, Schouten LJ, Soetekouw PM, de Bruïne AP, et al. (2008) Genetics and epigenetics of renal cell cancer. Biochim Biophys Acta 1785: 133-155.
19. Ying Y, Tao Q, (2009) Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers. Epigenetics 4: 307-312.
20. Costa VL, Henrique R, Ribeiro FR, Carvalho JR, Oliveira J, et al. (2010) Epigenetic regulation of Wnt signaling pathway in urological cancer. Epigenetics 5: 343-351.
21. Dai W, Teodoridis JM, Zeller C, Graham J, Hersey J, et al. (2011) Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res 17: 4052-4062.
22. Bilim V, Kawasaki T, Katagiri A, Wakatsuki S, Takahashi K, et al. (2000) Altered expression of beta-catenin in renal cell cancer and transitional cell cancer with the absence of beta-catenin gene mutations. Clin Cancer Res 6: 460-466.
23. Kim YS, Kang YK, Kim JB, Han SA, Kim KI, et al. (2000) Beta-catenin expression and mutational analysis in renal cell carcinomas. Pathol Int 50: 725-730.
24. Bruder E, Moch H, Ehrlich D, Leuschner I, Harms D, et al. (2007) Wnt signaling pathway analysis in renal cell carcinoma in young patients. Mod Pathol 20: 1217-1229.
25. Guillén-Ahlers H, (2008) Wnt signaling in renal cancer. Curr Drug Target 9: 591-600.
26. Saini S, Majid S, Dahiya R, (2011) The complex roles of Wnt antagonists in RCC. Nat Rev Urol 8: 690-699.
27. Hirata H, Hinoda Y, Nakajima K, Kikuno N, Yamamura S, et al. (2009) Wnt antagonist gene polymorphisms and renal cancer. Cancer 115: 4488-4503.
28. Urakami S, Shiina H, Enokida H, Hirata H, Kawamoto K, et al. (2006) Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res 12: 6989-6997.
29. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, et al. (2007) Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 13: 4740-4749.
30. Dahl E, Wiesmann F, Woenckhaus M, Stoehr R, Wild PJ, et al. (2007) Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene 26: 5680-5691.
31. Kawamoto K, Hirata H, Kikuno N, Tanaka Y, Nakagawa M, et al. (2008) DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines. Int J Cancer 123: 535-542.
32. Hirata H, Hinoda Y, Ueno K, Majid S, Saini S, et al. (2010) Role of secreted frizzled-related protein 3 in human renal cell carcinoma. Cancer Res 70: 1896-1905.
33. Kawakami K, Yamamura S, Hirata H, Ueno K, Saini S, et al. (2011) Secreted frizzled-related protein-5 is epigenetically downregulated and functions as a tumor suppressor in kidney cancer. Int J Cancer 128: 541-550.
34. Hirata H, Hinoda Y, Nakajima K, Kawamoto K, Kikuno N, et al. (2009) Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways. Clin Cancer Res 15: 5678-5687.
35. Hirata H, Hinoda Y, Nakajima K, Kawamoto K, Kikuno N, et al. (2011) Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. Int J Cancer 128: 1793-1803.
36. Kawakami K, Hirata H, Yamamura S, Kikuno N, Saini S, et al. (2009) Functional significance of Wnt inhibitory factor-1 gene in kidney cancer. Cancer Res 69: 8603-8610.
37. Lin YC, Ho JY, Cha TL, Chen A, Su SL, et al. (2010) Second primary malignancies in patients with carcinoma of the kidney: a hospital based study. J Med Sci 30: 199-206.
38. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr, (1985) Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109: 716-721.
39. Okoye UC, Malbon CC, Wang HY, (2008) Wnt and Frizzled RNA expression in human mesenchymal and embryonic (H7) stem cells. J Mol Signal 3: 16.
40. Kirikoshi H, Inoue S, Sekihara H, Katoh M, (2001) Expression of WNT10A in human cancer. Int J Oncol 19: 997-1001.
41. Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, et al. (2011) Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol 60: 644-661.
42. Wang X, Meng X, Sun X, Liu M, Gao S, et al. (2009) Wnt/beta-catenin signaling pathway may regulate cell cycle and expression of cyclin A and cyclin E protein in hepatocellular carcinoma cells. Cell Cycle 8: 1567-1570.
43. Sinnberg T, Menzel M, Ewerth D, Sauer B, Schwarz M, et al. (2011) β-Catenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistance. PLoS One 6: e23429.
44. Kirikoshi H, Sekihara H, Katoh M, (2011) WNT10A and WNT6, clustered in human chromosome 2q35 region with head-to-tail manner, are strongly coexpressed in SW480 cells. Biochem Biophys Res Commun 283: 798-805.
45. Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, et al. (2008) Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 452: 650-653.
46. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, et al. (2009) Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457: 608-611.
47. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, et al. (2006) Generation of a functional mammary gland from a single stem cell. Nature 439: 84-88.
48. Vaillant F, Asselin-Labat ML, Shackleton M, Forrest NC, Lindeman GJ, et al. (2008) The mammary progenitor marker CD61/beta 3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res 68: 7711-7717.
49. Teissedre B, Pinderhughes A, Incassati A, Hatsell SJ, Hiremath M, et al. (2009) MMTV-Wnt1 and-DeltaN89beta-catenin induce canonical signaling in distinct progenitors and differentially activate Hedgehog signaling within mammary tumors. PLoS One 4: e4537.
50. Wend P, Holland JD, Ziebold U, Birchmeier W, (2010) Wnt signaling in stem and cancer stem cells. Semin Cell Dev Biol 21: 855-863.
51. Serra R, Easter SL, Jiang W, Baxley SE, (2011) Wnt5a as an effector of TGFβ in mammary development and cancer. J Mammary Gland Biol Neoplasia 16: 157-167.
52. Uysal-Onganer P, Kypta RM, (2012) Wnt11 in 2011- the regulation and function of a non-canonical Wnt. Acta Physiol (Oxf) 204: 52-64.
53. Barker N, Clevers H, (2006) Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 5: 997-1014.
54. Königshoff M, Balsara N, Pfaff EM, Kramer M, Chrobak I, et al. (2008) Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS One 3: e2142.
55. Nakamura Y, Nawata M, Wakitani S, (2005) Expression profiles and functional analyses of Wnt-related genes in human joint disorders. Am J Pathol 167: 97-105.
56. Tulac S, Nayak NR, Kao LC, Van Waes M, Huang J, et al. (2003) Identification, characterization, and regulation of the canonical Wnt signaling pathway in human endometrium. J Clin Endocrinol Metab 88: 3860-3866.
57. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, et al. (2004) Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 101: 3118-3123.
58. Bomben R, Dal Bo M, Capello D, Benedetti D, Marconi D, et al. (2007) Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. Blood 109: 2989-2998.
59. You L, Kim J, He B, Xu Z, McCormick F, et al. (2006) Wnt-1 signal as a potential cancer therapeutic target. Drug News Perspect 19: 27-31.
60. You L, He B, Xu Z, Uematsu K, Mazieres J, et al. (2004) Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene 23: 6170-6174.
61. You L, He B, Xu Z, Uematsu K, Mazieres J, et al. (2004) An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res 64: 5385-5389.
62. Cheng XX, Wang ZC, Chen XY, Sun Y, Kong QY, et al. (2005) Correlation of Wnt-2 expression and beta-catenin intracellular accumulation in Chinese gastric cancers: relevance with tumour dissemination. Cancer Lett 223: 339-347.
63. Fu L, Zhang C, Zhang LY, Dong SS, Lu LH, et al. (2011) Wnt2 secreted by tumour fibroblasts promotes tumour progression in oesophageal cancer by activation of the Wnt/{beta}-catenin signalling pathway. Gut 60: 1635-1643.
64. Clément G, Braunschweig R, Pasquier N, Bosman FT, Benhattar J, (2006) Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus. Oncogene 25: 3084-3092.
65. Wang W, Xue L, Liu H, Wang P, Xu P, et al. (2010) Aberrant changes of Wnt2/beta-catenin signaling pathway induced by sodium nitroprusside in human esophageal squamous cell carcinoma cell lines. Cancer Invest 8: 230-341.
66. Pu P, Zhang Z, Kang C, Jiang R, Jia Z, et al. (2009) Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther 16: 351-361.
67. Park JK, Song JH, He TC, Nam SW, Lee JY, et al. (2009) Overexpression of Wnt-2 in colorectal cancers. Neoplasma 56: 119-123.
68. Katoh M, (2001) Frequent up-regulation of WNT2 in primary gastric cancer and colorectal cancer. Int J Oncol 19: 1003-1007.
69. Katoh M, Kirikoshi H, Terasaki H, Shiokawa K, (2001) WNT2B2 mRNA, up-regulated in primary gastric cancer, is a positive regulator of the WNT- beta-catenin-TCF signaling pathway. Biochem Biophys Res Commun 289: 1093-1098.
70. Nygren MK, Døsen G, Hystad ME, Stubberud H, Funderud S, et al. (2007) Wnt3A activates canonical Wnt signalling in acute lymphoblastic leukaemia (ALL) cells and inhibits the proliferation of B-ALL cell lines. Br J Haematol 136: 400-413.
71. Uraguchi M, Morikawa M, Shirakawa M, Sanada K, et al. (2004) Activation of WNT family expression and signaling in squamous cell carcinomas of the oral cavity. J Dent Res 83: 327-332.
72. Kim M, Lee HC, Tsedensodnom O, Hartley R, Lim YS, et al. (2008) Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol 48: 780-791.
73. Bengochea A, de Souza MM, Lefrançois L, Le Roux E, Galy O, et al. (2008) Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer 99: 143-150.
74. Wei W, Chua MS, Grepper S, So SK, (2011) Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin. Mol Cancer 10: 16.
75. Björklund P, Svedlund J, Olsson AK, Akerström G, Westin G, (2009) The internally truncated LRP5 receptor presents a therapeutic target in breast cancer. PLoS One 4: e4243.
76. Yan L, Della Coletta L, Powell KL, Shen J, Thames H, et al. (2011) Activation of the canonical Wnt/β-catenin pathway in ATF3-induced mammary tumors. PLoS One 6: e16515.
77. Bisson I, Prowse DM, (2009) WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 19: 683-697.
78. Tickenbrock L, Hehn S, Sargin B, Choudhary C, Bäumer N, et al. (2008) Activation of Wnt signalling in acute myeloid leukemia by induction of Frizzled-4. Int J Oncol 33: 1215-1221.
79. Thiago LS, Costa ES, Lopes DV, Otazu IB, Nowill AE, et al. (2010) The Wnt signaling pathway regulates Nalm-16 b-cell precursor acute lymphoblastic leukemic cell line survival and etoposide resistance. Biomed Pharmacother 64: 63-72.
80. Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, Rothberg BG, et al. (2009) Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci USA 106: 1193-1198.
81. Miyakoshi T, Takei M, Kajiya H, Egashira N, Takekoshi S, et al. (2008) Expression of Wnt4 in human pituitary adenomas regulates activation of the beta-catenin-independent pathway. Endocr Pathol 19: 261-273.
82. Liu X, Mazanek P, Dam V, Wang Q, Zhao H, et al. (2008) Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification. Oncogene 27: 1478-1488.
83. Carmon KS, Loose DS, (2008) Secreted frizzled-related protein 4 regulates two Wnt7a signaling pathways and inhibits proliferation in endometrial cancer cells. Mol Cancer Res 6: 1017-1028.
84. Zhang XL, Peng CJ, Peng J, Jiang LY, Ning XM, et al. (2010) Prognostic role of Wnt7a expression in ovarian carcinoma patients. Neoplasma 57: 545-551.
85. Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, et al. (2008) Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene 27: 596-603.
86. Chen K, Fallen S, Abaan HO, Hayran M, Gonzalez C, et al. (2008) Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival. Pediatr Blood Cancer 51: 349-355.
87. Yuan F, Zhou W, Zou C, Zhang Z, Hu H, et al. (2010) Expression of Oct4 in HCC and modulation to wnt/β-catenin and TGF-β signal pathways. Mol Cell Biochem 343: 155-162.
88. Bui TD, Rankin J, Smith K, Huguet EL, Ruben S, et al. (1997) A novel human Wnt gene, WNT10B, maps to 12q13 and is expressed in human breast carcinomas. Oncogene 14: 1249-1253.
89. Wend P, Wend K, Krum SA, Miranda-Carboni GA, (2102) The role of WNT10B in physiology and disease. Acta Physiol (Oxf) 204: 34-51.
90. Mazieres J, You L, He B, Xu Z, Lee AY, et al. (2005) Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis. Oncogene 24: 5396-5400.
91. Román-Gómez J, Cordeu L, Agirre X, Jiménez-Velasco A, San José-Eneriz E, et al. (2007) Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood 109: 3462-3469.